Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

To stop or not to stop, that is the question.

Seeman E.

Osteoporos Int. 2009 Feb;20(2):187-95. doi: 10.1007/s00198-008-0813-x.

PMID:
19096746
2.

Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

Seeman E.

Bone. 2007 Sep;41(3):308-17. Epub 2007 Jun 26. Review.

PMID:
17644058
3.

Who will benefit from antiresorptive treatment (bisphosphonates)?

Papapoulos SE.

Best Pract Res Clin Rheumatol. 2005 Dec;19(6):965-73. Review.

PMID:
16301190
4.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
5.

Stabilized severe osteoporosis: should the treatment be stopped?

Paccou J, Confavreux CB, David C, Leboime A, Mehsen N, Cortet B.

Joint Bone Spine. 2010 Dec;77 Suppl 2:S120-7. doi: 10.1016/S1297-319X(10)70007-5.

PMID:
21211749
6.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
7.

Combination therapy for postmenopausal osteoporosis.

Compston JE, Watts NB.

Clin Endocrinol (Oxf). 2002 May;56(5):565-9.

PMID:
12030903
8.

Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?

Hohenhaus MH, McGarry KA, Col NF.

Drugs. 2007;67(16):2311-21. Review.

PMID:
17983253
9.

Do not use bisphosphonate therapy indefinitely for fracture prevention.

[No authors listed]

Prescrire Int. 2008 Oct;17(97):214.

PMID:
19536944
10.

Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):207-11.

PMID:
16397977
11.

Recognition of women at risk for fracture and intervention with fast-acting therapies.

Derman R.

Int J Fertil Womens Med. 2006 Jul-Aug;51(4):183-90. Review.

PMID:
17184104
12.

[How to prevent early postmenopausal fracture risk? Proposition of a strategy].

Trémollieres F, Pouilles JM, Ribot C.

Gynecol Obstet Fertil. 2009 Jan;37(1):50-6. doi: 10.1016/j.gyobfe.2008.09.017. Epub 2008 Dec 24. French.

PMID:
19110461
13.

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.

Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.

PMID:
17618847
14.

Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis.

Miller PD.

Expert Opin Pharmacother. 2003 Dec;4(12):2253-8. Review.

PMID:
14640924
15.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
16.

Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.

Makras P, Hamdy NA, Zwinderman AH, Ballieux BE, Papapoulos SE.

Bone. 2009 May;44(5):766-71. doi: 10.1016/j.bone.2009.01.371. Epub 2009 Jan 31.

PMID:
19442613
17.

Osteoporosis: trials and tribulations.

Seeman E.

Am J Med. 1997 Aug 18;103(2A):74S-87S; discussion 87S-89S. Review.

PMID:
9302899
18.

Osteodensitometry in healthy postmenopausal women.

[No authors listed]

Prescrire Int. 2008 Apr;17(94):68-72.

PMID:
18536138
19.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
20.

Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?

Karsdal MA, Qvist P, Christiansen C, Tankó LB.

Drugs. 2006;66(15):1909-18. Review.

PMID:
17100403

Supplemental Content

Support Center